Balance Sheet

v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash $ 81,761 $ 85,838
Restricted cash 29,700 0
Accounts receivable, net 12,965 1,500
Grant receivable 117,359 56,359
Prepaid expenses 126,278 84,629
Total current assets 368,063 228,326
Property and equipment, net 89,707 102,843
Right to use assets 328,990 384,921
Other assets:    
Patents, net 10,795 11,385
Software development costs 47,980 47,980
Deposits, long term 44,520 44,520
Total other assets 103,295 103,885
Total assets 890,055 819,975
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $1,259,458 and $1,014,892, respectively 3,600,419 3,188,560
Deferred revenue, short term 34,981 34,981
Lease liability, short term 126,876 119,733
Notes payable 221,480 221,480
Notes payable, related parties 790,110 790,110
PPP loan, short term 21,828 31,580
Total current liabilities 4,795,694 4,386,444
Long term liabilities:    
PPP loan, long term 109,612 99,860
EIDL loan, long term 74,300 74,300
Royalty obligation, net of discount of $5,620,338 and $5,854,226, related parties 3,101,762 2,867,874
Lease liability, long term 250,291 315,672
Deferred revenue, long term 19,954 37,301
Total liabilities 8,351,613 7,781,451
Deficit:    
Common stock, $0.001 par value; 750,000,000 shares authorized, 7,082,285 and 6,698,968 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively 7,082 6,699
Common stock subscribed 100,000 100,000
Additional paid in capital 64,757,084 62,994,739
Accumulated deficit (72,227,195) (69,966,692)
Total deficit attributable to BioCorRx, Inc. (7,341,413) (6,843,638)
Non-controlling interest (120,145) (117,838)
Total deficit (7,461,558) (6,961,476)
Total liabilities and deficit 890,055 819,975
Series B Convertible Preferred Stock    
Deficit:    
Preferred stock value 5,616 5,616
Series A Convertible Preferred Stock    
Deficit:    
Preferred stock value $ 16,000 $ 16,000

Source